--- title: "SciSparc reports $4,436 thousand in cash" url: "https://aibio.space/news/scisparc-reports-4-436-thousand-cash-6-051-thousand-loss-first-half/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-09-30" section: "Listings" tickers: "NASDAQ:SPRC" source: "https://www.sec.gov/Archives/edgar/data/1611746/000121390026105319/ea030686801ex99-1.htm" summary: "SciSparc reported $4,436 thousand of cash and a $6,051 thousand net loss for the six months to June 30, 2026. Its own going concern note says these factors" --- By the aibio.space news desk. Sources - [SciSparc Ltd. 6-K (2026-09-30)](https://www.sec.gov/Archives/edgar/data/1611746/000121390026105319/ea030686801ex99-1.htm) - [SciSparc Ltd. 20-F (2026-04-29): business](https://www.sec.gov/Archives/edgar/data/1611746/000121390026049322/ea0286030-20f_scisparc.htm) - [SciSparc Ltd. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1611746/000121390021018407/) [SPRC](https://aibio.space/companies/scisparc/) 2026-09-30 # SciSparc reports $4,436 thousand in cash and $6,051 thousand loss for first half Tickers [SPRC](https://aibio.space/companies/scisparc/) SciSparc reported $4,436 thousand of cash and a $6,051 thousand net loss for the six months to June 30, 2026. Its own going concern note says these factors raise substantial doubt about its ability to continue as a going concern. ## Key facts - **Company**: SciSparc Ltd. (NASDAQ: SPRC) - **News type**: Listings - **Primary source**: [SciSparc Ltd. 6-K (2026-09-30)](https://www.sec.gov/Archives/edgar/data/1611746/000121390026105319/ea030686801ex99-1.htm) *The stone facade of a federal building. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* ## The first-half numbers SciSparc Ltd. (Nasdaq: [SPRC](https://aibio.space/companies/scisparc/)) furnished unaudited interim consolidated financial statements for the six months ended June 30, 2026 in a Form 6-K filed September 30, 2026. Revenues were $284 thousand, against $461 thousand a year earlier. The operating loss was $4,887 thousand, against $2,713 thousand, as general and administrative expenses rose to $3,198 thousand from $2,109 thousand. The net loss was $6,051 thousand, against $9,412 thousand. That comparison is not like for like. The prior-year figure includes a $5,973 thousand loss on impairment of loans, which the current period does not have. Net cash used in operating activities was $3,561 thousand, against $1,861 thousand a year earlier. Financing provided $3,288 thousand, including $1,598 thousand from share issuances and $1,690 thousand from convertible debentures and a promissory note. Cash and cash equivalents ended the period at $4,436 thousand, down from $4,591 thousand at December 31, 2025. ## Going concern and working capital Note 1 reports negative working capital of $1,371 thousand at June 30, 2026, and an accumulated deficit of $92,525 thousand. The company says its cash is not sufficient to fund planned operations for at least a year beyond the filing date, and that it depends on raising funds from existing and new investors. The note says these factors raise substantial doubt about the group's ability to continue as a going concern. ## The NeuroThera deal and the stake NeuroThera Labs, the company's subsidiary, closed its acquisition of 54.01% of CliniQuantum Ltd. on June 3, 2026. The purchase price was $6,501 thousand, made up of a share issuance valued at $4,512 thousand and two earn-out liabilities totaling $1,989 thousand. NeuroThera issued 56,600,000 common shares to the sellers and 2,829,999 more to arm's length finders. The allocation is preliminary and may be adjusted for up to one year. It shows an excess purchase price of $10,320 thousand. The financing earn-out assumes NeuroThera completes a financing of $2,500 thousand each year. The statements say SciSparc's holding in NeuroThera fell from 75% to 43.86% following the CliniQ transaction. ## The AutoMax loans SciSparc's bridge loans to AutoMax Motors Ltd. were increased by amendments to a total of $4,250 thousand. It made a further $2,000 thousand loan on February 27, 2025. The companies had agreed a merger in April 2024, but on October 6, 2025 they agreed to terminate it under a framework agreement. The termination followed a September 2025 investigation by the Israeli Securities Authority and Israeli Police, in which three senior AutoMax officials were arrested. On October 21, 2025, an Israeli court froze proceedings against AutoMax and appointed a trustee. The loans then became due immediately. SciSparc estimates a 90% probability that they will not be repaid, and it recorded a $5,973 thousand loss on impairment of the loans, which the income statement shows in the 2025 comparison period. The loans and accrued interest stood at $451 thousand at June 30, 2026. ## Convertible notes, warrants and equity On February 12, 2026, SciSparc signed an agreement with an institutional investor for convertible promissory notes of up to $10,000 thousand. The first note had a principal of $2,000 thousand and was sold for $1,800 thousand. The notes carry 4% interest, rising to 14% after a default, and are repayable in ten monthly installments starting 18 months after issue. The first warrant covers up to 3,651,554 shares at $4.9294, through February 12, 2029. The notes were carried at $2,336 thousand at June 30, 2026. The statements do not name the investor or any placement agent. Total equity was $11,271 thousand, but $7,326 thousand of that is non-controlling interest. Equity attributable to SciSparc's shareholders was $3,945 thousand, against $4,239 thousand at December 31, 2025. Shares outstanding were 580,973 at June 30, 2026, after the 1-for-9 Fifth Reverse Share Split took effect on March 4, 2026. Loss per share was $9.70 for the first half, against $159.87 a year earlier, both restated for the splits. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story SPRC SciSparc Ltd. NASDAQ ยท Israel Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/scisparc-reports-4-436-thousand-cash-6-051-thousand-loss-first-half/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "SciSparc reports $4,436 thousand in cash", 2026-09-30, https://aibio.space/news/scisparc-reports-4-436-thousand-cash-6-051-thousand-loss-first-half/